+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Cancer Immunotherapy Drug Discovery Outsourcing Market by Cancer Type, Drug Type, Service Type - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6010623
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Cancer Immunotherapy Drug Discovery Outsourcing Market grew from USD 1.60 billion in 2023 to USD 1.84 billion in 2024. It is expected to continue growing at a CAGR of 15.59%, reaching USD 4.41 billion by 2030.

The cancer immunotherapy drug discovery outsourcing market is primarily defined by its role in enabling pharmaceutical and biotechnology companies to engage external entities for the discovery and development of novel cancer immunotherapies. This necessity arises due to the burgeoning demand for advanced treatments, coupled with the complexity and high costs associated with in-house drug discovery processes. Outsourcing offers access to specialized expertise, cutting-edge technologies, and efficient timelines. Key applications include monoclonal antibodies, checkpoint inhibitors, cancer vaccines, and cell therapies. End-users primarily encompass pharmaceutical companies, research institutions, and academic centers. Market growth is significantly influenced by increasing cancer prevalence, advancements in biotechnology, and rising awareness of immunotherapy benefits. The latest opportunities lie in the expansion of personalized medicine programs, developments in bioinformatics for target identification, and strategic collaborations. It's advisable for companies to invest in partnerships with tech firms and academic institutions to exploit innovations in AI and machine learning that can streamline drug discovery processes. However, challenges such as stringent regulatory landscapes, high developmental costs, and intellectual property concerns pose considerable limitations to market expansion. Additionally, navigating the competitive landscape with patent cliffs and generic erosion is particularly challenging. Opportunities for innovation and research are abundant in the exploration of combination therapies, bispecific antibodies, and CAR-T technologies, which are currently on the rise. Continuous innovation in microfluidics and nanotechnology also presents potential breakthrough opportunities. The market tends to be characterized by rapid technological advancements, high competition, and a demand for cost-effective solutions. Companies poised for success are those that remain agile, leveraging the latest technological advancements while balancing cost efficiency with the pursuit of innovative, effective, and safe therapy options to meet global oncologic needs.

Understanding Market Dynamics in the Cancer Immunotherapy Drug Discovery Outsourcing Market

The Cancer Immunotherapy Drug Discovery Outsourcing Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising prevalence of cancer globally
    • Increasing awareness regarding immunotherapy among physicians and patients
    • Increasing investments for the development of cancer therapies
  • Market Restraints
    • High cost of drug development and treatment
  • Market Opportunities
    • Rise in clinical trials for development of efficient cancer immunotherapy
    • Increasing CDMO collaborations with pharmaceutical companies
  • Market Challenges
    • Stringent government regulations and guidelines

Exploring Porter’s Five Forces for the Cancer Immunotherapy Drug Discovery Outsourcing Market

Porter’s Five Forces framework further strengthens the insights of the Cancer Immunotherapy Drug Discovery Outsourcing Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Cancer Immunotherapy Drug Discovery Outsourcing Market

External macro-environmental factors deeply influence the performance of the Cancer Immunotherapy Drug Discovery Outsourcing Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Cancer Immunotherapy Drug Discovery Outsourcing Market

The Cancer Immunotherapy Drug Discovery Outsourcing Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Cancer Immunotherapy Drug Discovery Outsourcing Market

The Cancer Immunotherapy Drug Discovery Outsourcing Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Cancer Immunotherapy Drug Discovery Outsourcing Market

The Cancer Immunotherapy Drug Discovery Outsourcing Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Immunotherapy Drug Discovery Outsourcing Market, highlighting leading vendors and their innovative profiles. These include BPS Bioscience, Inc., Celentyx Ltd., Charles River Laboratories International, Inc., Covance, Inc., Crown Bioscience, Inc., Curia Inc., Dalton Pharma Services, DiscoverX Corporation, Eurofins Scientific, Evotec SE, Explicyte, Genscript Biotech Corporation, HD Biosciences Co., Ltd., Horizon Discovery Group PLC, ImmunXperts SA, Jubilant Life Sciences Limited, Labcorp, Oncodesign Precision Medicine Opm SA, Personalis, Inc., Promega Corporation, STC Biologics Inc., TCG Lifesciences Pvt. Limited, and WuXi AppTec Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Cancer Immunotherapy Drug Discovery Outsourcing Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Cancer Type
    • Breast
    • Colorectal
    • Head and Neck
    • Lung
    • Melanoma
    • Ovarian
    • Pancreatic
    • Prostate
  • Drug Type
    • Immunomodulators
    • Monoclonal Antibodies
    • Oncolytic Viral Therapies & Cancer Vaccines
  • Service Type
    • Cell-based Assays
    • Lead Screening & Characterization
    • Target Identification & Validation
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of cancer globally
5.1.1.2. Increasing awareness regarding immunotherapy among physicians and patients
5.1.1.3. Increasing investments for the development of cancer therapies
5.1.2. Restraints
5.1.2.1. High cost of drug development and treatment
5.1.3. Opportunities
5.1.3.1. Rise in clinical trials for development of efficient cancer immunotherapy
5.1.3.2. Increasing CDMO collaborations with pharmaceutical companies
5.1.4. Challenges
5.1.4.1. Stringent government regulations and guidelines
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Cancer Type
6.1. Introduction
6.2. Breast
6.3. Colorectal
6.4. Head and Neck
6.5. Lung
6.6. Melanoma
6.7. Ovarian
6.8. Pancreatic
6.9. Prostate
7. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Drug Type
7.1. Introduction
7.2. Immunomodulators
7.3. Monoclonal Antibodies
7.4. Oncolytic Viral Therapies & Cancer Vaccines
8. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Service Type
8.1. Introduction
8.2. Cell-based Assays
8.3. Lead Screening & Characterization
8.4. Target Identification & Validation
9. Americas Cancer Immunotherapy Drug Discovery Outsourcing Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Cancer Immunotherapy Drug Discovery Outsourcing Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Cancer Immunotherapy Drug Discovery Outsourcing Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.4. Strategy Analysis & Recommendation
LIST OF FIGURES
FIGURE 1. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET RESEARCH PROCESS
FIGURE 2. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2023 VS 2030 (%)
FIGURE 11. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
TABLE 1. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET DYNAMICS
TABLE 7. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BREAST, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COLORECTAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HEAD AND NECK, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LUNG, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY OVARIAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PANCREATIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PROSTATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLYTIC VIRAL THERAPIES & CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CELL-BASED ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD SCREENING & CHARACTERIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 28. ARGENTINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 31. BRAZIL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 32. BRAZIL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 33. BRAZIL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 34. CANADA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 35. CANADA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 36. CANADA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 37. MEXICO CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 38. MEXICO CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 39. MEXICO CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 44. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 45. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 46. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 47. ASIA-PACIFIC CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 48. AUSTRALIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 49. AUSTRALIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 50. AUSTRALIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 51. CHINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 52. CHINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 53. CHINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 54. INDIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 55. INDIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 56. INDIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 57. INDONESIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 58. INDONESIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 59. INDONESIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 60. JAPAN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 61. JAPAN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 62. JAPAN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 63. MALAYSIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 64. MALAYSIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 65. MALAYSIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 66. PHILIPPINES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 67. PHILIPPINES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 68. PHILIPPINES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 69. SINGAPORE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 70. SINGAPORE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 71. SINGAPORE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 72. SOUTH KOREA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 73. SOUTH KOREA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 74. SOUTH KOREA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 75. TAIWAN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 76. TAIWAN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 77. TAIWAN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 78. THAILAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 79. THAILAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 80. THAILAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 81. VIETNAM CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 82. VIETNAM CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 83. VIETNAM CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 88. DENMARK CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 89. DENMARK CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 90. DENMARK CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 91. EGYPT CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 92. EGYPT CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 93. EGYPT CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 94. FINLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 95. FINLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 96. FINLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 97. FRANCE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 98. FRANCE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 99. FRANCE CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 100. GERMANY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 101. GERMANY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 102. GERMANY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 103. ISRAEL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 104. ISRAEL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 105. ISRAEL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 106. ITALY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 107. ITALY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 108. ITALY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 109. NETHERLANDS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 110. NETHERLANDS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 111. NETHERLANDS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 112. NIGERIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 113. NIGERIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 114. NIGERIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 115. NORWAY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 116. NORWAY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 117. NORWAY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 118. POLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 119. POLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 120. POLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 121. QATAR CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 122. QATAR CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 123. QATAR CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 127. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 128. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 129. SAUDI ARABIA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 130. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 131. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 132. SOUTH AFRICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 133. SPAIN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 134. SPAIN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 135. SPAIN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 136. SWEDEN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 137. SWEDEN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 138. SWEDEN CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 139. SWITZERLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 140. SWITZERLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 141. SWITZERLAND CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 142. TURKEY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 143. TURKEY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 144. TURKEY CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 150. UNITED KINGDOM CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 151. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2023
TABLE 152. CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Cancer Immunotherapy Drug Discovery Outsourcing market, which are profiled in this report, include:
  • BPS Bioscience, Inc.
  • Celentyx Ltd.
  • Charles River Laboratories International, Inc.
  • Covance, Inc.
  • Crown Bioscience, Inc.
  • Curia Inc.
  • Dalton Pharma Services
  • DiscoverX Corporation
  • Eurofins Scientific
  • Evotec SE
  • Explicyte
  • Genscript Biotech Corporation
  • HD Biosciences Co., Ltd.
  • Horizon Discovery Group PLC
  • ImmunXperts SA
  • Jubilant Life Sciences Limited
  • Labcorp
  • Oncodesign Precision Medicine Opm SA
  • Personalis, Inc.
  • Promega Corporation
  • STC Biologics Inc.
  • TCG Lifesciences Pvt. Limited
  • WuXi AppTec Co., Ltd.

Methodology

Loading
LOADING...

Table Information